MedTrace Logo

Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

NCT02283905 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2020-09-29

No results posted yet for this study

Summary

All patients with pulmonary blastomycosis requiring mechanical ventilation will have their blood concentrations measured for the antifungal drugs, amphotericin-B and voriconazole; as well as an analysis of the susceptibility of their infecting species of blastomyces. This information will then be analyzed relative to their rate of clinical recovery from this serious fungal infection.

Conditions

  • Blastomycosis

Interventions

DRUG

amphotericin-B

continuously infused

DRUG

voriconazole

intravenously or orally administered

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Robert E. Ariano, Pharm.D. · St. Boniface Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2020-09-25
Completion
2020-09-25

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02283905 on ClinicalTrials.gov